Noninvasive vs. invasive arterial pressure during pediatric non cardiac surgery.

Minerva Anestesiol

Section of Anesthesiology and Intensive Care, Department of Health Sciences, University of Florence, Florence, Italy -

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0375-9393.23.17338-XDOI Listing

Publication Analysis

Top Keywords

noninvasive invasive
4
invasive arterial
4
arterial pressure
4
pressure pediatric
4
pediatric cardiac
4
cardiac surgery
4
noninvasive
1
arterial
1
pressure
1
pediatric
1

Similar Publications

National early warning score 2 plus non-invasive capnography and perfusion index to estimate poor outcomes in emergency departments.

Am J Emerg Med

January 2025

Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain; Emergency Department, Hospital Clínico Universitario, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.

Background: The study of the inclusion of new variables in already existing early warning scores is a growing field. The aim of this work was to determine how capnometry measurements, in the form of end-tidal CO2 (ETCO2) and the perfusion index (PI), could improve the National Early Warning Score (NEWS2).

Methods: A secondary, prospective, multicenter, cohort study was undertaken in adult patients with unselected acute diseases who needed continuous monitoring in the emergency department (ED), involving two tertiary hospitals in Spain from October 1, 2022, to June 30, 2023.

View Article and Find Full Text PDF

Background: Training opportunities, work satisfaction, and the factors that influence them according to gender and subspecialties are understudied among Japanese cardiologists.

Methods: We investigated the career development of Japanese cardiologists with an e-mail questionnaire. Feelings of inequality in training opportunities, work dissatisfaction, and reasons were assessed by examining the cardiologists' gender and invasiveness of subspecialties.

View Article and Find Full Text PDF

Skin-like bioelectronics offer a transformative technological frontier, catering to continuous and real-time yet highly imperceptible and socially discreet digital healthcare. The key technological breakthrough enabling these innovations stems from advancements in novel material synthesis, with unparalleled possibilities such as conformability, miniature footprint, and elasticity. However, existing solutions still lack desirable properties like self-adhesivity, breathability, biodegradability, transparency, and fail to offer a streamlined and scalable fabrication process.

View Article and Find Full Text PDF

Preclinical evaluation of the potential PARP-imaging probe [carbonyl-C]DPQ.

EJNMMI Radiopharm Chem

January 2025

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.

Background: Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for the repair of DNA single-strand breaks and have become key therapeutic targets in homologous recombination-deficient cancers, including prostate cancer. To enable non-invasive monitoring of PARP-1 expression, several PARP-1-targeting positron emission tomography (PET) tracers have been developed. Here, we aimed to preclinically investigate [carbonyl-C]DPQ as an alternative PARP-1 PET tracer as it features a strongly distinct chemotype compared to the frontrunners [F]FluorThanatrace and [F]PARPi.

View Article and Find Full Text PDF

Aims: A cardiovascular magnetic resonance (CMR) approach to non-invasively estimate left ventricular (LV) filling pressure was recently developed and shown to correlate with invasively measured pulmonary capillary wedge pressure (PCWP). We examined the association between CMR-estimated PCWP (CMR-PCWP) and other imaging and biomarker measures of congestion, and the effect of empagliflozin on these, in the SUGAR-DM-HF trial (NCT03485092).

Methods And Results: SUGAR-DM-HF enrolled 105 patients with heart failure with reduced ejection fraction (HFrEF) and pre-diabetes or type 2 diabetes who were randomly assigned to empagliflozin 10 mg or placebo once daily for 36 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!